You are here
- Home
- Drug Products
- All Drug Products
A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients with Parkinson’s Disease.
- Disease
- Parkinson's disease
- Drug Name
- AstraZeneca Neuroscience Development Drugs
- Generic Name
- AZD3241
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- IIa
- Start Date
- Jan 18, 1971
- Study Name
- D0490C00004
- Study Id
- D0490C00004
- ClinicalTrials.gov ID
- NCT01527695
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
